| Trial-Results center | |||
| Clinical trial results database |
 Feedback
 Home
|
This trial is included in the following systematic reviews and meta-analyses:
venous thrombosis
-
antithrombotics
-
all type of patients
venous thrombosis
-
heparin (UFH or LMWH)
-
all type of patients
Related trials
Lopaciuk, 3000 - subcutaneous heparin vs intravenous heparin
RE-COVER, 2009 - dabigatran vs vitamin K antagonists
Romera, 2009 - Tinzaparin vs acenocoumarol
Gonz�lez-Fajardo, 2008 - Enoxaparin vs coumarin
Botticelli DVT, 2008 - apixaban vs heparin/VKA
Einstein-DVT Dose-Ranging Study, 2008 - rivaroxaban vs heparin/VKA
VanGogh DVT, 2007 - idraparinux vs heparin/VKA
VanGogh PE, 2007 - idraparinux vs heparin/VKA
Daskalopoulos, 2005 - LMWH at home vs UFH in hospital
Fiessinger , 2005 - ximelagatran vs vitamin K antagonists
Chong, 2005 - LMWH at home vs UFH in hospital
Kearon, 2004 - 4 months vs 3 months
Ramacciotti, 2004 - LMWH at home vs UFH in hospital
MATISSE, 2004 - fondaparinux vs enoxaparin
Lee, 2003 - Dalteparin vs warfarin
Agnelli, 2003 - 6-12 months vs 3 months
Kakkar, 2003 - Bemiparin vs warfarin
Deitcher, 2003 - Enoxaparin vs warfarin
MATISSE PE, 2003 - fondaparinux vs heparin/VKA
Hull, 2002 - Tinzaparin vs warfarin
Meyer, 2002 - Enoxaparin vs warfarin
Agnelli, 2001 - 12 months vs 3 months
Merli (once daily vs UFH), 2001 - once daily enoxaparin vs UFH
Lopez-Beret, 2001 - Nadroparin vs acenocoumarol
Merli, 2001 - once daily enoxaparin vs twice daily enoxaparin
See also:
Agnelli study, 2001 |
|
Treatments
| Studied treatment |
continuation for 9 additional months; warfarin or acenocoumarol adjusted to achieve a target INR between 2.0 and 3.0
|
| Control treatment |
discontinuation (after 3 months months)
|
Patients
| Inclusion criteria | Patients ranging from 15 to 85 years old with a first episode of symptomatic idiopathic proximal deep venous thrombosis, as demonstrated by compression ultrasonography or venography; provided that they had completed three uninterrupted months of oral anticoagulant therapy without having a recurrence of thromboembolism or bleeding | ||
| Exclusion criteria | prolonged anticoagulant therapy for reasons other than venous thromboembolism; major psychiatric disorder; life expectancy shorter than two years; | ||
| Baseline characteristics |
|
Method and design
| Randomized effectives | NA / NA (studied vs. control) |
| Design | Parallel groups |
| Blinding | open |
| Follow-up duration | 33 months |
| Number of centre | 10 |
| Geographic area | Italy |
| Primary endpoint | Recurrent VTE |
Results
No results available for this trial - no clinical endpoint reported
Reference(s)
| Trials register # | NA |
-
Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W.
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators..
N Engl J Med 2001;345:165-9
Pubmed
|
Hubmed
| Fulltext
(c) 2004-2010 TrialResults-center - All Rights Reserved
Tweet this
notify a friend